Idenix Pharmaceuticals Has Returned 11.7% Since SmarTrend Recommendation (IDIX)
Comtex SmarTrend(R) - Fri Apr 11, 11:17AM CDT
SmarTrend identified a Downtrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on March 26th, 2014 at $6.30. In approximately 2 weeks, Idenix Pharmaceuticals has returned 11.75% as of today's recent price of $5.56.
Pipeline Update from Idenix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:55PM CDT
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
PR Newswire - Tue Apr 08, 12:15PM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 edging 1.08% lower to finish the trading session at 1,845.04. The losses were broad based as nine out of 10 sectors ended the session in negative. A number of stocks saw large movements, including Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Free technical research on PPHM, AGIO, IDIX and LXRX can be downloaded upon signing up at:
Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:51AM CDT
Idenix Pharmaceuticals Inc. was a big mover last session, as its shares rose over 12% on the day.
Why Idenix Pharmaceuticals, B&G Foods, and Petrobras Rose Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 07, 7:02PM CDT
Last week's memories of near-record closes for the Dow Jones Industrials faded further into the background Monday, as the Dow posted a decline of more than 1% amid growing concerns about the market's valuation. Even though more volatile sectors of...
MannKind vs. Idenix: Better Biotech Buy
David Williamson, The Motley Fool - Motley Fool - Mon Apr 07, 6:17PM CDT
In this video after a big day in the biotech sector, Motley Fool health-care analyst David Williamson takes investors through today's big winner and loser. Idenix is the winner for the day, up 10% after posting solid results in a...
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Idenix Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 07, 12:12PM CDT
What: Shares of Idenix Pharmaceuticals , a clinical-stage biopharmaceutical company developing therapies to treat human viral diseases, jumped as much as 14% after reporting data and updating the progress of its nucleotide prodrug inhibitor...
Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C
GlobeNewswire - Mon Apr 07, 6:06AM CDT
-- Idenix Reports Positive Proof-of-Concept Data for Lead Nucleotide Prodrug, IDX21437
52.5% Return Seen to Date on SmarTrend Idenix Pharmaceuticals Call (IDIX)
Comtex SmarTrend(R) - Tue Mar 25, 9:14AM CDT
SmarTrend identified an Uptrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on November 4th, 2013 at $4.43. In approximately 5 months, Idenix Pharmaceuticals has returned 52.54% as of today's recent price of $6.75.
Idenix Announces Nucleotide Prodrug (IDX21437) and NS5A Inhibitor (Samatasvir) Poster Presentations at 49th Annual Meeting of the European Association for the Study of the Liver
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced three poster presentations featuring clinical and preclinical data for the Company's nucleotide prodrug, IDX21437, and for samatasvir, Idenix's once-daily pan-genotypic NS5A inhibitor, at The International Liver Congress(TM) 2014, the 49th annual meeting of the European Association for the Study of the Liver (EASL), taking place in London, April 9-13, 2014. Full abstracts can now be viewed at the EASL Congress website.
Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case
GlobeNewswire - Mon Mar 24, 6:01AM CDT
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it intends to file an appeal to challenge the Oslo, Norway District Court's (the "Court"
Geron Held Up
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 7:51PM CDT
After zooming up on positive data for its telomerase inhibitor imetelstat in myelofibrosis and multiple myeloma, Geron came crashing back to earth this month when the biotech announced that the FDA was putting its clinical trial on hold due to...
Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register http://www.analystsreview.com/register
Idenix Files Lawsuit vs. Gilead Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:25PM CDT
Idenix files Sovaldi-related patent infringement lawsuit against Gilead
Biotech Stock Roundup: Biogen Up for S&P100, Geron Plunges on Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 19, 12:27PM CDT
Last week's highlights include Biogen's addition to S&P100, the FDA clinical hold on Geron's sole pipeline candidate and an improved outlook from Alexion.
Top Gainers under Review -- Research on Coeur Mining, Eagle Rock Energy Partners, Idenix Pharma, and WidePoint
PR Newswire - Wed Mar 19, 7:15AM CDT
On Tuesday, March 18, 2014, the US markets saw a positive sentiment with the NASDAQ Composite closing at 4,333.31, up 1.25%, the Dow Jones Industrial Average ending the session at 16,336.19, up 0.55% and the S&P 500 edging 0.72% higher to finish the trading session at 1,872.25. During the session, gains in the Information Technology, Health Care, and Energy sectors positively impacted the broader market. A number of stocks saw large movements, including Coeur Mining Inc. (NYSE: CDE), Eagle Rock Energy Partners L.P. (NASDAQ: EROC), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and WidePoint Corp. (AMEX: WYY). Free technical research on CDE, EROC, IDIX and WYY can be downloaded upon signing up at:
4 Stocks Under $10 to Trade for Breakouts
at The Street - Tue Mar 18, 8:41PM CDT
These under-$10 stocks are within range of triggering breakout trades.